Novartis NVS announced that the FDA has ... the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is ...

Novartis NVS obtains FDA ... disease. Approximately 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis. The approval Vanrafia marks the third ...

Novartis has made kidney disorders ... trying to slow disease progression. The lone therapeutic is tolvaptan, brand name Jynarque, an Otsuka Pharmaceutical drug approved by the FDA in 2018 for ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA has now ... Berger’s disease, in which antibodies accumulate in the kidney, causing ...

Novartis plans ... known as miroRNAs. The drug is expected to enter a late-stage study this year to test it for the treatment of autosomal dominant polycystic kidney disease.

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...

On Thursday, the U.S. Food and Drug Administration (FDA ... for Fabhalta and its second within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval ...

Novartis will ... pharmaceutical firm a drug prospect called farabursen, which recently completed a Phase 1b study in people with autosomal dominant polycystic kidney disease, or ADPKD.

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...